Burning Rock Biotech (BNR) Payables (2019 - 2026)

Burning Rock Biotech (BNR) has reported Payables for 8 consecutive years, with $2.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Payables fell 46.46% year-over-year to $2.7 million; the TTM figure through Mar 2026 stood at $2.7 million (down 46.46% YoY), while the FY2025 annual figure was $5.9 million, up 25.66% from the prior year.
• Payables came in at $2.7 million for Q1 2026 at Burning Rock Biotech, down from $5.8 million in the prior quarter.
• The five-year high for Payables was $15.6 million in Q1 2022, with the low at $2.7 million in Q4 2023.
• Average Payables over 5 years is $5.5 million, with a median of $4.5 million recorded in 2025.
• Across the five-year window, Payables soared 100.5% in 2022 and plunged 76.74% in 2023, its largest moves.
• Year by year, Payables stood at $7.4 million in 2022, then slumped by 63.94% to $2.7 million in 2023, then surged by 78.73% to $4.8 million in 2024, then rose by 21.91% to $5.8 million in 2025, then sank by 53.84% to $2.7 million in 2026.
• According to Business Quant data, Payables over the past three periods registered $2.7 million, $5.8 million, and $4.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.